Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Oct 13:30:83-86.
doi: 10.1016/j.jdcr.2022.10.007. eCollection 2022 Dec.

Durvalumab-associated generalized morphea with overlapping vitiligo

Julianna Martel  1 , Woo Cheal Cho  2 , John S Runge  3 , Anisha B Patel  1   4 , Jean Tayar  5 , Karin Woodman  6 , Celyne Bueno Hume  7 , Jonathan Curry  2   8 , Meghan Heberton  9
Affiliations
Case Reports

Durvalumab-associated generalized morphea with overlapping vitiligo

Julianna Martel et al. JAAD Case Rep. .
No abstract available

Keywords: PD-L1; PD-L1, programmed cell death receptor ligand 1; durvalumab; immunotherapy; irAEs, immune-related adverse events; morphea; vitiligo.

PubMed Disclaimer

Conflict of interest statement

None disclosed.

Figures

Fig 1
Fig 1
Durvalumab-associated morphea with overlapping vitiligo. Clinical features show smooth, tightened, thickened skin with overlying ill-defined hypopigmented patches on the lower portion of both the legs (A). Perioral sclerosis causes the reduced opening of the mouth (B). The dorsal aspect of the hand shows depigmentation without underlying morphea. There is no sclerodactyly of the hand and no telangiectasias of nail beds (C).
Fig 2
Fig 2
Durvalumab-associated morphea with overlapping vitiligo. Histologic features from punch biopsy on back. Sections showed skin and subcutis with squared silhouette and diffuse dermal fibrosis, with thickened dermal collagen and atrophic adnexal structures (A and B, Hematoxylin-eosin; original magnification: A, ×10; B, ×100). There was a sparse superficial perivascular lymphocytic infiltrate and mild edema in the papillary dermis. An immunohistochemical study with anti-SOX10 highlighted rare, scattered basally located junctional melanocytes (arrowheads) that were markedly reduced in number. (C, Original magnification: ×100.)
See this image and copyright information in PMC

References

    1. Paz-Ares L., Dvorkin M., Chen Y., et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929–1939. doi: 10.1016/S0140-6736(19)32222-6. - DOI - PubMed
    1. Ellis S.R., Vierra A.T., Millsop J.W., Lacouture M.E., Kiuru M. Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features. J Am Acad Dermatol. 2020;83(4):1130–1143. doi: 10.1016/j.jaad.2020.04.105. - DOI - PMC - PubMed
    1. Bhardwaj M., Chiu M.N., Pilkhwal Sah S. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance. Cutan Ocul Toxicol. 2022;41(1):73–90. doi: 10.1080/15569527.2022.2034842. - DOI - PubMed
    1. Terrier B., Humbert S., Preta L.H., et al. Risk of scleroderma according to the type of immune checkpoint inhibitors. Autoimmun Rev. 2020;19 doi: 10.1016/j.autrev.2020.102596. - DOI - PubMed
    1. Tjarks B.J., Kerkvliet A.M., Jassim A.D., Bleeker J.S. Scleroderma-like skin changes induced by checkpoint inhibitor therapy. J Cutan Pathol. 2018;45:615–618. doi: 10.1111/cup.13273. - DOI - PubMed

Publication types